Mainz Biomed N.V. (NASDAQ:MYNZ)’s traded shares stood at 1.82 million during the last session, with the company’s beta value hitting 0.07. At the close of trading, the stock’s price was $0.25, to imply a decrease of -4.76% or -$0.01 in intraday trading. The MYNZ share’s 52-week high remains $3.39, putting it -1256.0% down since that peak but still an impressive 24.0% since price per share fell to its 52-week low of $0.19. The company has a valuation of $5.38M, with an average of 2.01 million shares in intraday trading volume over the past 10 days and average of 1.79 million shares over the past 3 months.
Mainz Biomed N.V. (NASDAQ:MYNZ) trade information
After registering a -4.76% downside in the last session, Mainz Biomed N.V. (MYNZ) has traded red over the past five days. The 5-day price performance for the stock is 21.06%, and -37.39% over 30 days. With these gigs, the year-to-date price performance is -78.79%. Short interest in Mainz Biomed N.V. (NASDAQ:MYNZ) saw shorts transact 0.72 million shares and set a 0.39 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mainz Biomed N.V. (MYNZ) estimates and forecasts
Looking at statistics comparing Mainz Biomed N.V. share performance against respective industry, we note that the company has outperformed competitors. Mainz Biomed N.V. (MYNZ) shares are -77.22% down over the last 6 months, with its year-to-date growth rate higher than industry average at 45.68% against 17.80%. The rating firms project that company’s revenue will grow 34.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is 220k. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 300k.
MYNZ Dividends
Mainz Biomed N.V. has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is VONTOBEL HOLDING LTD. with 25000.0 shares, or about 0.1181% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $10025.0.
